Thelin sitaxsentan regulatory update

ENCY submitted an MAA for 100 mg once-daily oral Thelin sitaxsentan to treat pulmonary arterial hypertension (PAH). Thelin has Orphan Drug designation in the EU for PAH and chronic thromboembolic pulm...